|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZWILCH |
Gene summary for ZWILCH |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZWILCH | Gene ID | 55055 |
| Gene name | zwilch kinetochore protein | |
| Gene Alias | KNTC1AP | |
| Cytomap | 15q22.31 | |
| Gene Type | protein-coding | GO ID | GO:0000070 | UniProtAcc | Q9H900 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55055 | ZWILCH | LZE7T | Human | Esophagus | ESCC | 3.14e-04 | 3.96e-01 | 0.0667 |
| 55055 | ZWILCH | LZE8T | Human | Esophagus | ESCC | 3.54e-05 | 1.37e-01 | 0.067 |
| 55055 | ZWILCH | LZE24T | Human | Esophagus | ESCC | 3.42e-03 | 1.23e-01 | 0.0596 |
| 55055 | ZWILCH | LZE6T | Human | Esophagus | ESCC | 1.44e-02 | 1.53e-01 | 0.0845 |
| 55055 | ZWILCH | P2T-E | Human | Esophagus | ESCC | 3.32e-16 | 3.87e-01 | 0.1177 |
| 55055 | ZWILCH | P4T-E | Human | Esophagus | ESCC | 3.20e-16 | 4.73e-01 | 0.1323 |
| 55055 | ZWILCH | P5T-E | Human | Esophagus | ESCC | 1.68e-10 | 2.54e-01 | 0.1327 |
| 55055 | ZWILCH | P8T-E | Human | Esophagus | ESCC | 7.85e-13 | 2.54e-01 | 0.0889 |
| 55055 | ZWILCH | P9T-E | Human | Esophagus | ESCC | 3.21e-04 | 1.10e-01 | 0.1131 |
| 55055 | ZWILCH | P10T-E | Human | Esophagus | ESCC | 1.02e-08 | 2.21e-01 | 0.116 |
| 55055 | ZWILCH | P12T-E | Human | Esophagus | ESCC | 3.40e-06 | 1.94e-01 | 0.1122 |
| 55055 | ZWILCH | P15T-E | Human | Esophagus | ESCC | 4.61e-10 | 3.22e-01 | 0.1149 |
| 55055 | ZWILCH | P16T-E | Human | Esophagus | ESCC | 2.76e-17 | 3.24e-01 | 0.1153 |
| 55055 | ZWILCH | P20T-E | Human | Esophagus | ESCC | 2.52e-02 | 6.92e-02 | 0.1124 |
| 55055 | ZWILCH | P21T-E | Human | Esophagus | ESCC | 2.18e-11 | 2.30e-01 | 0.1617 |
| 55055 | ZWILCH | P22T-E | Human | Esophagus | ESCC | 1.32e-03 | 1.00e-01 | 0.1236 |
| 55055 | ZWILCH | P23T-E | Human | Esophagus | ESCC | 1.38e-12 | 3.88e-01 | 0.108 |
| 55055 | ZWILCH | P24T-E | Human | Esophagus | ESCC | 4.74e-10 | 2.72e-01 | 0.1287 |
| 55055 | ZWILCH | P26T-E | Human | Esophagus | ESCC | 2.48e-11 | 2.32e-01 | 0.1276 |
| 55055 | ZWILCH | P27T-E | Human | Esophagus | ESCC | 4.62e-13 | 1.53e-01 | 0.1055 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:014001414 | Esophagus | ESCC | mitotic nuclear division | 218/8552 | 287/18723 | 6.17e-26 | 1.78e-23 | 218 |
| GO:000007011 | Esophagus | ESCC | mitotic sister chromatid segregation | 138/8552 | 168/18723 | 1.37e-22 | 2.63e-20 | 138 |
| GO:00008194 | Esophagus | ESCC | sister chromatid segregation | 157/8552 | 202/18723 | 8.41e-21 | 1.33e-18 | 157 |
| GO:003304416 | Esophagus | ESCC | regulation of chromosome organization | 145/8552 | 187/18723 | 3.80e-19 | 4.31e-17 | 145 |
| GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
| GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
| GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
| GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
| GO:00988133 | Esophagus | ESCC | nuclear chromosome segregation | 187/8552 | 281/18723 | 1.00e-12 | 4.36e-11 | 187 |
| GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
| GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
| GO:190199013 | Esophagus | ESCC | regulation of mitotic cell cycle phase transition | 191/8552 | 299/18723 | 1.35e-10 | 3.94e-09 | 191 |
| GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
| GO:00000754 | Esophagus | ESCC | cell cycle checkpoint | 117/8552 | 169/18723 | 4.47e-10 | 1.17e-08 | 117 |
| GO:0010639110 | Esophagus | ESCC | negative regulation of organelle organization | 215/8552 | 348/18723 | 8.20e-10 | 2.01e-08 | 215 |
| GO:003450211 | Esophagus | ESCC | protein localization to chromosome | 70/8552 | 92/18723 | 2.54e-09 | 5.64e-08 | 70 |
| GO:00070934 | Esophagus | ESCC | mitotic cell cycle checkpoint | 90/8552 | 129/18723 | 2.49e-08 | 4.69e-07 | 90 |
| GO:00519833 | Esophagus | ESCC | regulation of chromosome segregation | 67/8552 | 91/18723 | 5.42e-08 | 9.66e-07 | 67 |
| GO:00070883 | Esophagus | ESCC | regulation of mitotic nuclear division | 78/8552 | 110/18723 | 6.96e-08 | 1.21e-06 | 78 |
| GO:00070912 | Esophagus | ESCC | metaphase/anaphase transition of mitotic cell cycle | 49/8552 | 62/18723 | 7.65e-08 | 1.33e-06 | 49 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZWILCH | SNV | Missense_Mutation | c.1082N>A | p.Ile361Asn | p.I361N | Q9H900 | protein_coding | tolerated(0.19) | benign(0.096) | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZWILCH | SNV | Missense_Mutation | c.245N>G | p.Ser82Cys | p.S82C | Q9H900 | protein_coding | tolerated(0.06) | benign(0.007) | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| ZWILCH | SNV | Missense_Mutation | rs763594625 | c.1423G>A | p.Val475Ile | p.V475I | Q9H900 | protein_coding | tolerated(0.18) | benign(0.005) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| ZWILCH | SNV | Missense_Mutation | novel | c.859N>G | p.Leu287Val | p.L287V | Q9H900 | protein_coding | tolerated(0.67) | benign(0.159) | TCGA-BH-A1FU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| ZWILCH | SNV | Missense_Mutation | novel | c.1486N>C | p.Ile496Leu | p.I496L | Q9H900 | protein_coding | tolerated(0.77) | benign(0.049) | TCGA-E2-A15S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| ZWILCH | SNV | Missense_Mutation | c.1039N>A | p.Asp347Asn | p.D347N | Q9H900 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EK-A2IP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZWILCH | SNV | Missense_Mutation | c.776N>C | p.Arg259Thr | p.R259T | Q9H900 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-Q1-A73P-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZWILCH | SNV | Missense_Mutation | rs562042882 | c.575N>T | p.Arg192Ile | p.R192I | Q9H900 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZWILCH | SNV | Missense_Mutation | c.220N>G | p.Thr74Ala | p.T74A | Q9H900 | protein_coding | tolerated(0.33) | benign(0.001) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| ZWILCH | SNV | Missense_Mutation | c.181G>T | p.Val61Leu | p.V61L | Q9H900 | protein_coding | tolerated(0.2) | benign(0.001) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |